ASCO 2023 – Behind Astellas comes Elevation
Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.
Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.
